Login to Your Account

One-third of foreign drug plants never inspected by the FDA

By Mari Serebrov
Regulatory Editor

Friday, January 20, 2017

The FDA still has a ways to go to ensure the safety and quality of the U.S. drug supply chain, as it has yet to inspect nearly 1,000 foreign plants that manufacture drug substances for the market.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription